Category Archives: Cf

For a 22-year-old rookie who has had only four regular-season at-bats, Cristian Pache has good reason to look comfortable with Atlanta Braves starters in spring training.

Pache already has delivered offensive and defensive highlights on one of the game's biggest stages. Pache unveiled his talents with six starts in center field in Atlanta's NLCS loss to the Los Angeles Dodgers. His second-deck homer and above-the-wall catch were enticing previews of the big plays he might provide as a starter in 2021.

The big-game exposure changed Pache's offseason. Suddenly, he didn't blend in as easily when he returned to his home in the Dominican Republic.

I think it was a little different, Pache said Wednesday through a translator. When I went back home I was recognized a little bit more around town."

The postseason experience was especially valuable after the coronavirus pandemic took away the minor league season. Already this spring, manager Brian Snitker sees evidence of the young outfielders growth as a hitter.

He looks like a different guy now than when he came into camp a year ago, Snitker said Wednesday.

Different?

Just how his setup and his swing is more consistent, working better than a year ago, is probably the biggest thing, Snitker said. Hes cleaned things up offensively."

Pache earned the respect of his teammates with his performance in the postseason spotlight. Third baseman Austin Riley said Pache should receive huge benefits from the experience.

From me speaking from experience of going through it, just such high-intensity games that those are and for him to make some really great plays in the outfield and hitting a home run, I think that only boosted his confidence, Riley said Thursday.

Pache's opportunity came after Adam Duvall suffered a strained left oblique muscle in Game 1 of the NLCS. Following Duvall's injury, Ronald Acua Jr. moved to right field.

The Braves starting outfield this season likely will include Marcell Ozuna in left field, Acua in right field and either Pache or Ender Inciarte in center field. Duvall has signed with Miami and Nick Markakis remains a free agent.

Inciarte was left off Atlanta's 2020 postseason roster after hitting only .190 in the regular season. It was the latest sign of Inciarte's offensive decline and leaves Pache the opening to win the starting job.

He was 4 for 22 with a homer and four RBIs in the postseason. He also made a leaping catch above the wall to rob Max Muncy of a home run.

Pache already is regarded as the Braves' best defensive outfielder, even though Inciarte won three consecutive Gold Gloves from 2016-18. Pache's power is still developing and he also has yet to take advantage of his speed.

Fantasy players should take note: There could be more stolen bases in Pache's future.

Hes not a polished player yet, Snitker said. Theres still room to grow. Hes really fast. Hes not a real good base stealer. Weve encouraged him to run more. I think guys have to want to do that. Thats a state of mind type of thing, I think. A mentality that guys have. He has the speed, I think, to be a guy like that.

The rookie's defensive grace has earned comparisons with former Braves center fielder Andruw Jones, who won 10 Gold Gloves. Now a special assistant with the Braves, Jones has closely monitored Pache's progress.

We talked coming into spring training, Pache said of Jones. I think he noticed the work I put in during the offseason and I think he was very pleased with what he saw from me during the offseason.

NOTES: Snitker said RHP Mike Soroka remains on schedule in his comeback from surgery to repair a torn right Achilles tendon. There havent been any setbacks and hes checking all their boxes on a daily basis, Snitker said. ... IF Jack Mayfield, who was designated for assignment on Wednesday, was traded to the Los Angeles Angels for cash considerations. Mayfield's move cleared a spot for OF Guillermo Heredia, who was claimed off waivers from the New York Mets.

___

More AP MLB coverage: https://apnews.com/hub/MLB

See the original post here:

Braves rookie CF Pache banking on postseason in bid to start - New Haven Register

No player followed Tampa Bays offseason as closely as Kevin Kiermaier, whos thankful for one potential cost-cutting move the reigning AL champion Rays didnt make.

The 30-year-old defensive whiz, set to make $11.5 million in 2021, was the subject of weeks of trade speculation this winter following the teams loss in the World Series. Hes grateful to still be the face of the franchise in spring training.

I wasnt walking on eggshells saying, Oh, this might be my last day. But Id be lying if I didnt say some thoughts crept in my mind here or there, Kiermaier said following a workout in Port Charlotte, Florida.

Im thrilled to be here. I dont want to be anywhere else, the three-time Gold Glove center fielder said. I know how the business side of things work. Seeing my name in trade speculation felt more real than ever.

So much so that at one point Kiermaier reached out to general manager Erik Neander, who says its important to treat any player who might be the subject of such talks with an appropriate amount of respect as the Rays go about their business.

One of the keys to Tampa Bays ability to remain competitive while being outspent by most teams has been a penchant for making shrewd trades with an eye on the future, stockpiling promising young talent and keeping the payroll relatively low.

While the Rays didnt receive an offer for Kiermaier that Neander felt was too good to resist, the club did make a major move in trading 2018 AL Cy Young Award winner Blake Snell to the San Diego Padres.

We have a certain formula for how we do things getting talent, giving away talent to get talent. Its hard to go against what Erik Neander, the front office, management, and what those guys have done. We put out a great roster each and every year, Kiermaier said.

Its tough to see a great talent like Blake walk away, but the guys were bringing in, its hard not to be excited about that, the outfielder added. We have such great depth in our organization that theres no reason to panic.

A .248 career hitter, Kiermaier is coming off a productive postseason in which he homered once against the New York Yankees in the AL Divisional Series and twice against the Los Angeles Dodgers while batting .368 in the World Series. Hes under contract through at least 2022, with Tampa Bay holding a $13 million club option for 2023 that includes a $2.5 million buyout.

Although his greatest value to the Rays is as the centerpiece of one of baseballs top defenses, manager Kevin Cash stressed Kiermaier continues to evolve as a hitter even if his batting average, or where he hits in the lineup, doesnt always reflect that.

I think KK, year by year, is kind of learning what makes him good and how he is able to complement the rest of our lineup. I think hes finally recognizing that him being one of the nine in the batting order is more than enough to play his role, Cash said.

Kiermaier, who turns 31 in April, is just ecstatic to be preparing to help the Rays defend the AL pennant.

I was a little worried at times. This is an organization that has given me the world, the center fielder said. Ive loved every second Ive been here, and Im happy to still be here.

___

More AP MLB:https://apnews.com/MLBandhttps://twitter.com/AP_Sports

Go here to read the rest:

Spring Training 2021: Rays fan-favorite CF Kiermaier happy to remain with the team after trade rumors - Sports Talk Florida

For a 22-year-old rookie who has had only four regular-season at-bats, Cristian Pache has good reason to look comfortable with Atlanta Braves starters in spring training.

Javascript is required for you to be able to read premium content. Please enable it in your browser settings.

kAm!2496 2=C625J 92D 56=:G6C65 @776?D:G6 2?5 5676?D:G6 9:89=:89ED @? @?6 @7 E96 82>6VD 3:886DE DE286D]k^Am

kAmw6 F?G6:=65 9:D E2=6?ED H:E9 D:I DE2CED 😕 46?E6C 7:6=5 😕 pE=2?E2VD }{r$ =@DD E@ E96 {@D p?86=6D s@586CD] w:D D64@?5564< 9@>6C 2?5 23@G6E96H2== 42E49 H6C6 6?E:4:?8 AC6G:6HD @7 E96 3:8 A=2JD 96 >:89E AC@G:56 2D 2 DE2CE6C 😕 a_a`]k^Am

kAm%96 3:882>6 6IA@DFC6 492?865 !2496VD @77D62D@?] $F556?=J[ 96 5:5?VE 3=6?5 😕 2D 62D:=J H96? 96 C6EFC?65 E@ 9:D 9@>6 😕 E96 s@>:?:42? #6AF3=:4]k^Am

kAmx E9:?< :E H2D 2 =:EE=6 5:776C6?E[ !2496 D2:5 (65?6D52J E9C@F89 2 EC2?D=2E@C] (96? x H6?E 324< 9@>6 x H2D C64@8?:K65 2 =:EE=6 3:E >@C6 2C@F?5 E@H?]Qk^Am

kAm%96 A@DED62D@? 6IA6C:6?46 H2D 6DA64:2==J G2=F23=6 27E6C E96 4@C@?2G:CFD A2?56>:4 E@@< 2H2J E96 >:?@C =628F6 D62D@?] p=C625J E9:D DAC:?8[ >2?286C qC:2? $?:E<6C D66D 6G:56?46 @7 E96 J@F?8 @FE7:6=56CD 8C@HE9 2D 2 9:EE6C]k^Am

kAmw6 =@@6 :?E@ 42>A 2 J62C 28@[ $?:E<6C D2:5 (65?6D52J]k^Am

kAms:776C6?Enk^Am

kAmyFDE 9@H 9:D D6EFA 2?5 9:D DH:?8 😀 >@C6 4@?D:DE6?E[ H@C<:?8 36EE6C E92? 2 J62C 28@[ :D AC@323=J E96 3:886DE E9:?8[ $?:E<6C D2:5] w6D 4=62?65 E9:?8D FA @776?D:G6=J]Qk^Am

kAm!2496 62C?65 E96 C6DA64E @7 9:D E62>>2E6D H:E9 9:D A6C7@C>2?46 😕 E96 A@DED62D@? DA@E=:89E] %9:C5 32D6>2? pFDE:? #:=6J D2:5 !2496 D9@F=5 C646:G6 9F86 36?67:ED 7C@> E96 6IA6C:6?46]k^Am

kAmuC@> >6 DA62<:?8 7C@> 6IA6C:6?46 @7 8@:?8 E9C@F89 :E[ ;FDE DF49 9:89:?E6?D:EJ 82>6D E92E E9@D6 2C6 2?5 7@C 9:> E@ >2<6 D@>6 C62==J 8C62E A=2JD 😕 E96 @FE7:6=5 2?5 9:EE:?8 2 9@>6 CF?[ x E9:?< E92E @?=J 3@@DE65 9:D 4@?7:56?46[ #:=6J D2:5 %9FCD52J]k^Am

kAm!2496VD @AA@CEF?:EJ 42>6 27E6C p52> sFG2== DF776C65 2 DEC2:?65 =67E @3=:BF6 >FD4=6 😕 v2>6 ` @7 E96 }{r$] u@==@H:?8 sFG2==VD :?;FCJ[ #@?2=5 p4F2 yC] >@G65 E@ C:89E 7:6=5]k^Am

kAm%96 qC2G6D DE2CE:?8 @FE7:6=5 E9:D D62D@? =:<6=J H:== :?4=F56 |2C46== ~KF?2 :? =67E 7:6=5[ p4F2 :? C:89E 7:6=5 2?5 6:E96C !2496 @C t?56C x?4:2CE6 :? 46?E6C 7:6=5] sFG2== 92D D:8?65 H:E9 |:2>: 2?5 }:4< |2C<2<:D C6>2:?D 2 7C66 286?E]k^Am

kAmx?4:2CE6 H2D =67E @77 pE=2?E2VD a_a_ A@DED62D@? C@DE6C 27E6C 9:EE:?8 @?=J ]`h_ 😕 E96 C68F=2C D62D@?] xE H2D E96 =2E6DE D:8? @7 x?4:2CE6VD @776?D:G6 564=:?6 2?5 =62G6D !2496 E96 @A6?:?8 E@ H:? E96 DE2CE:?8 ;@3]k^Am

kAmw6 H2D c 7@C aa H:E9 2 9@>6C 2?5 7@FC #qxD 😕 E96 A@DED62D@?] w6 2=D@ >256 2 =62A:?8 42E49 23@G6 E96 H2== E@ C@3 |2I |F?4J @7 2 9@>6 CF?]k^Am

kAm!2496 2=C625J 😀 C682C565 2D E96 qC2G6DV 36DE 5676?D:G6 @FE7:6=56C[ 6G6? E9@F89 x?4:2CE6 H@? E9C66 4@?D64FE:G6 v@=5 v=@G6D 7C@> a_`e`g] !2496VD A@H6C 😀 DE:== 56G6=@A:?8 2?5 96 2=D@ 92D J6E E@ E2<6 25G2?E286 @7 9:D DA665]k^Am

kAmu2?E2DJ A=2J6CD D9@F=5 E2<6 ?@E6i %96C6 4@F=5 36 >@C6 DE@=6? 32D6D 😕 !2496VD 7FEFC6]k^Am

kAmw6D ?@E 2 A@=:D965 A=2J6C J6E[ $?:E<6C D2:5] %96C6D DE:== C@@> E@ 8C@H] w6D C62==J 72DE] w6D ?@E 2 C62= 8@@5 32D6 DE62=6C] (6G6 6?4@FC2865 9:> E@ CF? >@C6] x E9:?< 8FJD 92G6 E@ H2?E E@ 5@ E92E] %92ED 2 DE2E6 @7 >:?5 EJA6 @7 E9:?8[ x E9:?<] p >6?E2=:EJ E92E 8FJD 92G6] w6 92D E96 DA665[ x E9:?<[ E@ 36 2 8FJ =:<6 E92E]k^Am

kAm%96 C@@<:6VD 5676?D:G6 8C246 92D 62C?65 4@>A2C:D@?D H:E9 7@C>6C qC2G6D 46?E6C 7:6=56C p?5CFH y@?6D[ H9@ H@? `_ v@=5 v=@G6D] }@H 2 DA64:2= 2DD:DE2?E H:E9 E96 qC2G6D[ y@?6D 92D 4=@D6=J >@?:E@C65 !2496VD AC@8C6DD]k^Am

kAm(6 E2=<65 4@>:?8 :?E@ DAC:?8 EC2:?:?8[ !2496 D2:5 @7 y@?6D] x E9:?< 96 ?@E:465 E96 H@C< x AFE :? 5FC:?8 E96 @77D62D@? 2?5 x E9:?< 96 H2D G6CJ A=62D65 H:E9 H92E 96 D2H 7C@> >6 5FC:?8 E96 @77D62D@?]k^Am

Get Unlimited Access

$3 for 3 Months

Subscribe Now

Support local journalism reporting on your community

* New Subscribers Only* Digital Subscription Only After the initial selected subscription period your subscription rate will auto renew at $8.00 per month.

Follow this link:

Braves rookie CF Pache banking on postseason performance in bid to start - Times Daily

TipRanks

Lets talk about risk and the big picture. Its an appropriate time, as the big risk presented by the COVID-19 pandemic is finally receding thanks to the ongoing vaccination program. COVID is leaving behind an economy that was forced into shutdown one year ago while in the midst of a great expansion, boosted by the deregulation policies. While the new Biden Administration is busy reversing many Trump policies, at least for now the economy is rebounding. And this brings us to risk. A time of economic growth and rebound is a forgiving time to move toward risk investments, as general economic growth tends to lift everything. Two strategists from JPMorgan have recently chimed in, promoting the view that the markets fundamentals are still sound, and that small- to mid-cap sector is going to keep rising. First, on the general conditions, quant strategist Dubravko Lakos-Bujas wrote, Although the recent technical selloff and short squeeze is receiving a lot of attention, we believe the positive macro setup, improving fundamentals and COVID-19 outlook, strength of the US consumer, as well as the reflation theme remain the bigger forces at play. Not only should this drive further equity upside, but it remains favorable for continued rotation into economic reopening Building on this, Eduardo Lecubarr, chief of the Small/Mid-Cap Strategy team, sees opportunity for investors now, especially in the smaller value stocks. We stick to our view that 2021 will be a stockpickers paradise with big money-making opportunities if you are willing to go against the grain Many macro indicators did fall in January but SMid-Caps and equities in general continued to edge higher, Lecubarr noted. And if you are prone to look at high-risk, small- to mid-cap stocks, youll find yourself drawn to penny stocks. The risk involved with these plays scares off the faint hearted as very real problems like weak fundamentals or overwhelming headwinds could be masked by the low share prices. So, how should investors approach a potential penny stock investment? By taking a cue from the analyst community. These experts bring in-depth knowledge of the industries they cover and substantial experience to the table. Bearing this in mind, we used TipRanks database to find two compelling penny stocks, according to Wall Street analysts. Both tickers boast a Strong Buy consensus rating and could climb over 200% higher in the year ahead. CNS Pharmaceuticals (CNSP) We will start with CNS Pharmaceuticals, a biotechnology company with a focus on the treatment of glioblastomas, a class of aggressive tumors that attack the braid and spinal cord. These cancers, while rare, are almost always terminal, and CNS is working a new therapy designed to more effectively cross the blood-brain barrier to attack glioblastoma. Berubicin, CNSs flagship drug candidate, is an anthracycline, a potent class of chemotherapy drugs derived from the Streptomyces bacteria strains, and used in the treatment of a wide variety of cancers. Berubicin is the first drug in this class to show promise against glioblastoma cancers. The drug candidate has completed its Phase 1 clinical trial, in which 44% of patients showed a clinical response. This number included one patient who showed a Durable Complete Response, defined as a demonstrated lack of detectable cancer. Following the success of the Phase 1 study, CNS applied for, and received, FDA approval of its Investigational New Drug application. This gives the company the go-ahead to conduct a Phase 2 study on adult patients, an important next step in the development of the drug. CNS plans to start the mid-stage trial in 1Q21. Based on the potential of the companys asset in glioblastoma, and with its share price at $2.22, several analysts believe that now is the time to buy. Among the bulls is Brooklines 5-star analyst Kumaraguru Raja who takes a bullish stance on CNSP shares. Until now, the inability of anthracyclines to cross the blood brain barrier prevented its use for treatment of brain cancers. Berubicin is the first anthracycline to cross the blood-brain barrier in adults and access brain tumors Berubicin has promising clinical data in a Phase 1 trial in recurrent glioblastoma (rGBM) and has Orphan drug designation for treatment of malignant gliomas from the FDA. We model approval of Berubicin for treatment of recurrent glioblastoma in 2025 based on the Phase 2 data with 55% probability of success for approval. We model peak sales of $533 million in 2032, Raja opined. CNS pipeline also includes WP1244 (novel DNA binding agent) that is 500x more potent than daunorubicin in inhibiting tumor cell proliferation is expected to enter the clinic in 2021 In vivo testing in orthotopic models of brain cancer showed high uptake of WP1244 by brain and subsequent antitumor activity, the analyst added. To this end, Raja rates CNSP a Buy, and his $10 price target implies room for a stunning 350% upside potential in the next 12 months. (To watch Rajas track record, click here) What does the rest of the Street have to say? 3 Buys and 1 Hold add up to a Strong Buy consensus rating. Given the $8.33 average price target, shares could climb ~275% in the year ahead. (See CNSP stock analysis on TipRanks) aTyr Pharma (LIFE) The next stock were looking at, aTyr Pharma, has a focus on inflammatory disease. Its leading drug candidate, ATYR1923, is a Neuropilin-2 (NRP2) agonist, working through the receptor proteins expressed by the NRP2 gene. These pathways are important for cardiovascular development and disease, and play a role in the inflammatory lung disease pulmonary sarcoidosis. In December, the company reported that the drug candidate had completed enrollment of 36 patients in a Phase 1b/2a clinical trial, testing the drug in the treatment of pulmonary sarcoidosis. Results of the current study are expected in 3Q21, and will inform further trials of ATYR1923, including against other forms of inflammatory lung disease. On a more immediate note, in early January the company announced top-line results of another Phase 2 clinical involving ATRY1923 this time in the treatment of patients hospitalized with severe respiratory complications from COVID-19. The results were positive, showing that a single dose of ATYR1923 (at 3 mg/kg) resulted in a 5.5-day median recovery time. Overall, of the patients dosed in this manner, 83% saw recovery in less than one week. Covering LIFE for Roth Capital, 5-star analyst Zegbeh Jallah noted, We like the risk profile here, with two shots on goal, and updated data details from the COVID study is expected in the coming months. Also announced recently, is that data from aTyr's Pulmonary Sarcoidosis program, will be reported in 3Q21 the success of either of these studies could result in a doubling or more of the market cap as these opportunities appear to barely be accounted for by investors. In line with his optimistic approach, Jallah gives LIFE shares a Buy rating and his $15 price target suggests an impressive 277% potential upside for the coming year. (To watch Jallahs track record, click here) Other analysts are on the same page. With 2 additional Buy ratings, the word on the Street is that LIFE is a Strong Buy. On top of this, the average price target is $13.33, suggesting robust growth of ~236% from the current price of $3.97. (See LIFE stock analysis on TipRanks) To find good ideas for penny stocks trading at attractive valuations, visit TipRanks Best Stocks to Buy, a newly launched tool that unites all of TipRanks equity insights. Disclaimer: The opinions expressed in this article are solely those of the featured analysts. The content is intended to be used for informational purposes only. It is very important to do your own analysis before making any investment.

Go here to read the rest:

CF Industries Holdings, Inc. Announces Dates for Full Year and Fourth Quarter 2020 Results and Conference Call - Yahoo Finance

Gunnar Esiason and Emily Kramer-Golinkoff, Opinion contributors Published 7:00 a.m. ET Feb. 4, 2021

There are many questions surrounding Covid-19 vaccines, one of which is whether vaccines can be mixed and matched. Veuers Johana Restrepo has more. Buzz60

When it comes to getting vaccinated, why are many Americans with cystic fibrosis behind people working remotely, smokers, and cannabis growers?

In March, the term underlying condition was used toreassurehealthy Americans about their risk as COVID-19 overwhelmed New York Citys hospitals. Media reports saidoverandoverthat underlying health conditions presented an enormous amount of risk for Americans.

Yet, in many states people living with serious underlying conditions are still waiting for COVID-19 vaccines, prioritized below individuals with lower risk. Suddenly, it seems underlying health conditions are considered nothigh risk enough.

We live with cystic fibrosis (CF), a rare and fatal genetic disease associated with respiratory decline and failure. In 2019, the median age of death for individuals with CF in the United States was32.4 years old. And that'sunder the best of circumstances, notduring a pandemic.

When cases of COVID-19 started mounting nationwide, our patient community wasquickly urgedto stock up on supplies and stay home.Like the millions of Americans with underlying conditions, our goal was topreventexposure to COVID-19.

More than 30,000 people in the United States have CF. As of mid-January, at least799 individuals with CF have contracted COVID-19 in the U.S. with almost15% requiring hospitalization,according to a webinarhostedby the Cystic Fibrosis Foundation. According to preliminary data from theEuropean Cystic Fibrosis Society,the hospitalization rate for confirmed COVID-19 cases in Europeis almost 28%.

The risk for bad outcomes from COVID-19 increasesefor CF patientswith advanced lung disease, diabetes, or if they have received a double lung transplant.

Clearly, access to COVID-19 vaccines couldsubstantially reduce the risk of severe outcomesfrom the virus.

We have watched lower risk populations,including hospital employeeswithout direct patient careresponsibilities, universityfacultyable to teach remotely, and vaccine chasers receive their shots.

The specific prioritization varies state by state, but people with serious underlying conditions are finding themselves at the back of the line across the country, often because they are younger in age.

In Pennsylvania, people with CF are waiting in line behindsmokersand in Maryland, they are waiting behindcannabis growers. InWashingtonandMichigan, people with CF may have to wait until the spring or summer.

We allowed the opioid epidemic to play out: FDA's Janet Woodcock failed to stop the opioid epidemic

In some parts of the country, likeNorth CarolinaandCalifornia, vaccines are beingallocated by agerather thanrisk of serious outcomes, thereby leaving people with life-shortening diseases like CF behind.

Why are people with underlying health conditions who may have substantial risk for bad outcomes from COVID-19 being forced to wait for vaccines?

It is because we are stuck in a high-risk limbo.In some ways, orders to stay at home as much as possible worked, but now they are being used against us.

Because of our conditionssmall patient population sizeand our strict adherence to social distancing guidelines, states don't have complete information when it comes to the risks we face aftercontracting COVID-19. Imperfect data should not beused to set policy.

With advanced stage disease, I (Emily) am at particularly high risk. I have not left my house aside from a daily masked and socially distanced walk since March. I have not stepped foot in a grocery store or restaurant, and I have had to convert all of my medical care to telehealth. While telehealth has many benefits, the reality remains that a zoom call with ones doctors is not a substitute for in-person care, nor is it always possible.

Emily Kramer-Golinkoff in Philadelphia in July 2018.(Photo: Cheyenne Gil)

Disability advocates are rightly frustrated with vaccine allocation. CF is not the only condition to be disadvantaged in the rollout. People living with asthma, dementia, hypertension, liver disease, andother rareconditionsare also having towait behind healthy Americans.

Only one of us (Emily) has been able to receive the first dose of a vaccine, while the other (Gunnar) has had no luck so far. We are a microcosm of the frustration our patient community faces in gaining access to vaccines.

Instead, we aretold to stay home.

Now, it is almost as if staying home is presented to us as an alternative to vaccination. Chronic conditions often require in-person medical care that put us at high risk for exposure. In addition, people with CF and their family members rely on jobs for rent, food and health insurance just like everyone else that cannot always be done remotely. They alsohave children that go to schooland require child care. Just staying home is simply untenable for many.

Beyond the practical considerations, the suggestion that people with underlying conditions just stay home while we wait for later phases of the rollout is a solution steeped in discrimination. Providing vaccinations to lower risk people makes society accessible again for able-bodied people, while those of us with underlying medical conditions and disabilities are tucked away, expected to put our lives on hold, and wait.

Virginia fails to protect elderly: My parents caught COVID while vaccines languish unused

The insistence that we simply stay home denies our worth and value to society and treats us as second class citizens. The effect is a perpetuation of systemic ableism and widening of pre-existing inequity among sick and disabled populations.

Just staying home is not a substitute for vaccines.

Gunnar Esiason in Hanover, New Hampshire, in February 2020.(Photo: Family handout)

Highly effective vaccines are finally available. Now the onus is on policy makers to allocate them justly and equitably. That includes providing them to people with serious underlying conditions. This is particularly critical now as new coronavirusvariantsemerge in the US.

After all, for many of us with serious underlying conditions, a vaccine now versus in a few weeks or months can be the difference between life and death.

Gunnar Esiason, aMaster of Business Administration/Master of Public Healthcandidate at the Tuck School of Business at Dartmouth, lives with cystic fibrosis and is a rare disease patient leader with the BoomerEsiason Foundation. Follow him on Twitter @G17Esiason

Emily Kramer-Golinkoff, a Master of Bioethics,lives with advanced stage cystic fibrosis and is theco-founder of Emilys Entourage, which promotes research and drug development for Cystic Fibrosis,and a patient advocate and speaker. Follow Emily on Twitter at @emilykg1 and Emilys Entourage at @EmilysEntourage.

Autoplay

Show Thumbnails

Show Captions

Read or Share this story: https://www.usatoday.com/story/opinion/2021/02/04/covid-19-vaccinations-underlying-conditions-cystic-fibrosis-column/4376586001/

View post:

Having an underlying health condition doesn't mean we move up the COVID-19 vaccine line - USA TODAY

In April 2020, CF PharmTech and Chengdu Shangyi launched the "Home-Based Recovery Program for Discharged Covid-19 Patients". Under the guidance of Professor Li Jian'an, a member of the American Academy of Medical Sciences and Director of the Rehabilitation Medical Center of the First Affiliated Hospital of Nanjing Medical University, they successfully conducted studies of discharged Covid-19 patients using sports rehabilitation remote monitoring by "R Plus Health" App.

The clinical results exceeded everyone's expectations. Professor Li Jian'an concluded that the effect of sports rehabilitation monitoring for patients using the App was comparable to the effect from care given patients in the "Mobile Cabin Hospital" in Wuhan. The companies jointly launch the free "R Plus Health" App globally today.

The App is the world's clinically proven and effective, home-based rehabilitation treatment for Covid-19 patients. It is the first "patented digital therapy" approved by the NMPA(National Medical Products Administration). The main function of the App is its remote intelligent cardiopulmonary/muscle/nutrition assessment, combining the wearable equipment with prepackaged medicinal supplements.

The App will assist in improving the cardiopulmonary endurance and immunity of Covid-19 patients, susceptible populations, high-risk contacts, elderly people and children with poor immunity. Once users register, the App carries out intelligent assessments including questionnaires, and cardiopulmonary endurance and body function tests. After an evaluation, users can access a personalized exercise program including sports type, intensity, length of time and frequency. Users simply need to follow the sports training videos and do the exercises. The effect will be enhanced if the App is connected to intelligent equipment.

Since the outbreak of Covid-19, more than 100 million people have been diagnosed worldwide, and the number of infected individuals is increasing rapidly. It has become a global pandemic. Join the "R Plus Health" App to enhance physical fitness, improve immunity and fight against the coronavirus.

How to download:1.Search for "R Plus Health" App in the Apple Store or Google Play2.Click the link: https://download.rplushealth.cn/app/patient

SOURCE CF PharmTech, Inc.

See original here:

CF PharmTech and Chengdu Shangyi Launch the "Home-Based Recovery Program for Discharged Covid-19 Patients" and Announce Today's Global...

Once regarded as one of the Philadelphia Phillies top young talents, Scott Kingery did not have the 2020 that we were all expecting from him. After a nasty bout with COVID-19 leading into the shortened season, Kingery simply never got his feet under him. He finished the year with career-worsts across the board, slashing a measly .159/.283/.511. Kingerys defense was equally as suspect, as he actually finished with a negative defensive WAR on the year (-0.4).

It was a brutal 2020 campaign for the young infielder/outfielder, one that was constantly riddled with nagging injuries and bouts of inconsistencies. Anytime it looked like he was finally starting to find a rhythm, hed immediately fall back into a slump highlighted by lots of strikeouts and miscues in the field.

With all that said, theres still little reason to be 100% out on the former second round pick. He had an encouraging season in 2019 (career-high .788 OPS, 2.8 WAR), and hes still one of the better athletes on the Philadelphia Phillies roster. While he might struggle to snag himself an everyday role at second base the position he won a Gold Glove at in the minor leagues theres a possibility he finds himself a new starting gig in the Phillies outfield this season.

With Didi Gregorius now under contract for the next two seasons, the Phillies actually have a bit of a logjam when it comes to their infield. Didi is obviously the teams shortstop, Alec Bohm and Rhys Hoskins should be locking down the corners, and then Jean Segura likely takes second base. While the Phillies could in theory rotate Segura and Kingery at 2B to get them both playing time (like they did in 2020), it might make more sense for Joe Girardi to finally commit to Kingery as a full-time center fielder.

Due to his elite athleticism, Kingery has spent a good amount of time in the outfield throughout his three-year career. Hes logged 636 career innings as an outfielder, with 547 of them coming in center. While hes not been *great* by any stretch of the imagination out in CF, he did post a perfect fielding percentage at the position in 2020, at least showing signs of potential.

While the infield might be a more natural fit for Kingery based on his minor league experience, the Phillies are lacking in outfield depth. Andrew McCutchen is on his last legs, Roman Quinn can be a liability at times, and Adam Haseley has still failed to earn the trust of Girardi as an everyday option himself.

Barring any sort of last minute outfield additions, the Phillies would be wise to at least continue to cross-train Kingery as a second baseman and center fielder. On days where McCutchen needs a rest, lining up Kingery and Haseley as the center and left fielders wouldnt be the worst thing in the world.

While most still share the belief that Kingery needs to get everyday reps at 2B to continue to develop, at some point, playing time starts to become a factor. As long as Segura remains on the roster, itll be tough for Scott to be the full-time starter at second base. If taking over CF means getting daily action in the lineup, its something the Phillies should consider.

Here is the original post:

Philadelphia Phillies: Could Scott Kingery end up as the everyday CF? - Section 215

Kay Dee Market Insights (KDMI) recently published market research report on the globalCF & CFRP Market, this market research report provides detailed analysis of market drivers, challenges, opportunity analysis, and trends, along with various key insights into the market research report. The report on global CF & CFRP market demonstrates the important aspects that are anticipated to shape the growth of the market over the forecast period. The study also includes the analysis of the market size & forecast for the different segments and geographies.

The growth of this market is attributed towards major pertaining factors including: the increase in the demand for high-performance materials with high strength-to-weight ratio, good tensile strength, and electrical conductivity, the increasing use of carbon fiber composite materials in the aerospace industry, the rise in demand for lightweight vehicles so as to achieve fuel efficiency and production of electricity, the growing focus on renewable energy sources, exponential reduction in cost of carbon fibers, thegrowing demand for better performing products in the defense industry and the increasing focus on production of electricity from renewable source etc.

Access Exclusive Sample Report on CF & CFRP Market with Covid -19 Impacthttps://www.kdmarketinsights.com/sample/6891

The global CF & CFRP market research study aims to provide comprehensive analysis of market dynamics including the growth factors of the market which helps the clients to understand the market, market barriers & issues, industry trends and opportunities which can exhibit the current and future status of the market. Along with this, the report is also focused on the analysis of Porters Five Forces which defines the five forces including the buyers bargaining power, suppliers bargaining power, the threat of new entrants, the threat of substitutes, and degree of competition in the global CF & CFRP market.

Key Segments Covered in the Global CF & CFRP Market:

Market Forecast Analysis for 2019-2025

Growth Drivers & Barriers, Market Trends, Market Opportunities, Porters Five Forces Analysis, Trade Analysis

Market Overview, Industry Development, Market Maturity, Value Chain Analysis

Impact Analysis of Coronavirus Disease (COVID-19)

Regional & Country Level Analysis

Market Segment Trend and Forecast

Market Analysis and Various Recommendations

Key Market Driving Factors

Competitive Landscape: Company Market Share & Market Positioning, Company Profiling, Recent Industry News.

Impact of Coronavirus Disease (COVID-19) on Global CF & CFRP Market

The market research report explains the impact of coronavirus disease (COVID-19) on global CF & CFRP market, covering the major points of industry:

Impact analysis of COVID-19 on the global CF & CFRP market over the upcoming years.

Analysis of each region & country will be listed, to identify the issues caused by the coronavirus disease on the market.

Various strategies adopted by the major & prominent market players in order to survive in the situation of COVID-19 lockdown.

Explore Full Report With TOC and List of Figure of CF & CFRP Market with Covid -19 Impact https://www.kdmarketinsights.com/product/6891/cf-&-cfrp-market

Market Segmentation:

The research offers a comprehensive analysis of global CF & CFRP market with respect to following sub-markets:

By Source:

Virgin

Recycled

By End-use Industry:

Aerospace & Defense

Wind Energy

Automotive

Sporting Goods

Civil Engineering

Pipe & Tank

Marine

Electrical & Electronics

Medical

Others

ByRaw Material Type:

Pan-Based Carbon Fiber

Small-Tow (<24k)

Large-Tow (>24k)

Pitch-Based Carbon Fiber

Rayon-Based Carbon Fiber

ByResin Type:

Thermosetting CFRP

Epoxy

Polyester

Vinyl Ester

Others

Thermoplastic CFRP

Polypropylene

Polyethylene

Polyethylene Terephthalate

Others

By Manufacturing Process:

Lay-Up Process

Compression Molding Process

Resin Transfer Molding Process

Filament Winding Process

Injection Molding Process

Pultrusion Process

Others

Regional Information:

The report analyses the market by geographies i.e. North America, Europe, Asia Pacific, Latin America & Middle East & Africa. Further, the regions are fragmented into the country and regional groupings:

North America (U.S. & Canada)

Europe (Germany, United Kingdom, France, Italy, Spain, Russia, and Rest of Europe)

Asia Pacific (China, India, Japan, South Korea, Indonesia, Taiwan, Australia, New Zealand, and Rest of Asia Pacific)

Latin America (Brazil, Mexico, and Rest of Latin America)

Middle East & Africa (GCC (Saudi Arabia, UAE, Bahrain, Kuwait, Qatar, Oman), North Africa, South Africa, and Rest of Middle East & Africa)

Competitive Landscape

The market research report highlights the competitive landscape of the global CF & CFRP market, market share and positioning of all the major players in the industry. In addition, the report also profiles various major & niche key market players in the global CF & CFRP market including:

Solvay

Hyosung

Formosa Plastic Corporation

Dowaksa

Kureha Corporation

Toray Industries Inc

Mitsubishi Chemical Holdings

Hexcel Corporation

Check Our Exclusive Offer and Get Instant Discount on CF & CFRP Market https://www.kdmarketinsights.com/discount/6891

About Us:

KD Market Insights offers a comprehensive database of syndicated research studies, customized reports, and consulting services. These reports are created to help in making smart, instant, and crucial decisions based on extensive and in-depth quantitative information, supported by extensive analysis and industry insights.

Our dedicated in-house team ensures the reports satisfy the requirement of the client. We aim at providing value service to our clients. Our reports are backed by extensive industry coverage and is made sure to give importance to the specific needs of our clients. The main idea is to enable our clients to make an informed decision, by keeping them and ourselves up to date with the latest trends in the market.

Contact Us:

KD Market Insights

150 State Street, Albany,

New York, USA 12207

+1 (518) 300-1215

Email:sales@kdmarketinsights.com

Website:www.kdmarketinsights.com

Continued here:

CF & CFRP Market Report The demand for the Market will drastically increase in the Future Forecast 2025 KSU | The Sentinel Newspaper - KSU | The...

In Episode 71 of the Third Sub Podcast, Alexandre Gangue-Ruzic and Samuel Rowan dive into the latest Vancouver Whitecaps and MLS news from this past week, before finishing off with some more MLS kit chatter.

Welcome back to another episode of the Third Sub Podcast!

In this episode, Alex and Sam are back, as usual, this time to chat all things Vancouver Whitecaps and MLS.

Up first, they catch up on the Whitecaps news of the week, as they look at some of the confirmed transactions that have happened in the past week.

First, they look at a confirmed departure, as David Milinkovics contract was officially terminated this week, before looking at some of the names that signed new deals in the past week, as Andy Rose officially re-signed (and became an assistant coach for the Caps U19 team!), while Caps Super Draft pick David Egbo and longtime USL veteran Evan Newton signed deals to join the team.

After that, they look at how the CBA negotiations have progressed over the last week, giving some thoughts on the multiple extensions of the negotiating deadline by MLS, breaking down what sort of message this whole process has delivered.

To round off the episode, they then tip their hat to Club de Foot Montreal and the incredible work theyve put in behind the scenes to build a sneaky-good team, before devolving into some more MLS kit discussion and speculation.

If you have Twitter, make sure to check out The Third Sub Podcast @thirdsubpod!

The Third Sub can be found on Spotify, Google Play, Apple Podcasts and Anchor. It can also now be found on Breaker, Overcast, Pocket Casts and Radio Public, so if you have any of those platforms installed, you can now find it on them.

(We are no longer uploading to Soundcloud, but you can still find the first two episodes there, if interested.)

Apple Podcasts

Google Play

Breaker

Overcast

Pocket Casts

Like Loading...

Related

See the rest here:

The Third Sub Episode 71: Whitecaps make moves, CF Montreal continue to build, and some other MLS chatter - Between The Sticks

It was not only Filipino superstar Rolando Dy who experienced a fruitful 2020 because even his home promotion garnered noteworthy recognition for its effort to work through the so-called new normal last year.

Staying true to its commitment to deliver top-notch mixed martial arts action to fans around the world, FightBook MMA bestowed the Global Promotion of the Year award on BRAVE Combat Federation for the fourth year in a row.

Its no surprise to me that BRAVE CF won the award. In 2020, theyre one of the few promotions in the world that dared to take the first step and brought hope to fighters like me who were exploring different means to survive during the pandemic. Thats truly commendable, Dy said.

Founded by His Highness Shaikh Khaled bin Hamad Al Khalifa in 2016, the organization overcame an array of challenges caused by the global health crisis in 2020, finding a way to hold a total of 12 live events in countries such as Slovenia, Romania, Sweden, and Bahrain.

Looking back at 2020, Bahrain turned into an isolated fight hub dubbed as Kombat Kingdom to host five of the promotions 12 shows.

Moreover, BRAVE CF came to the rescue of the struggling European MMA scene by staging six cards in six weeks behind closed doors.

The year 2020 also witnessed the coronation of new world champions such as Amin Ayoub at lightweight and Mohammad Fakhreddine at middleweight.

Meanwhile, new contenders emerged through the pandemic-raged year with the likes of Dy, Muhammad Mokaev, Mochamed Machaev, and Benoit Saint Denis establishing themselves in their respective divisions.

The Bahrain-based MMA outfit paved the way for Dys career resurgence. He had a sensational 2020 that saw him clinch the prestigious BRAVE CF Fighter of the Year trophy with two remarkable victories as a lightweight.

Most recently, it was announced that Dy signed a brand new multi-fight contract with BRAVE CF.

They treat fighters with respect, and thats very important to us. I am grateful to be part of this promotion and for the opportunity they gave me last year, he stated.

They can count on me that I will represent the promotion to the best of my ability.

BRAVE CF 46 in Sochi, Russia was the companys curtain-raiser this year, featuring Eldar Eldarov who successfully defended his super lightweight title against Leonardo Mafra in the headliner.

The promotion is expected to announce its next event in the coming weeks.

Go here to see the original:

Rolando Dy attests to BRAVE CF's recognition as top global organization - Tiebreaker Times